Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Key facts
- Who runs it
- University of Arkansas
- Where
- Little Rock, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 55 people enrolled
- Started
- 26 Jul 2023
- Ended
- 23 Aug 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood draw
- FACIT-F and Pain Scales
- Record updated
- 8 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Diagnosed with NF1
- Not the first degree relative (biological parent, sibling, or child) of the NF1 patient who is in the NF1 group
Other criteria
- NF1 Group:
Where in United States
- University of Arkansas for Medical SciencesLittle Rock, United States
About the trial
What the trial wants to find out
Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitochondria. Patients will also answer questions regarding symptoms like fatigue and pain.
The 2 groups in the trial
- NF1 Group
This study will look to enroll 40 to 45 adults over 18 years old diagnosed with NF1.
Treatment: Blood draw and FACIT-F and Pain Scales
- Control Group
This study will look to enroll 10 to 15 adults over 18 years old without NF1.
Treatment: Blood draw
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 May 2025